German subsidiary obtains $74 million term loan
ST. LOUIS, May 6 /PRNewswire-FirstCall/ --
2009 First Quarter Highlights
- Net sales decreased to $339 million from $517 million in the first quarter of 2008
- Adjusted EBITDA decreased to $56 million from $95 million in the first quarter of 2008
- Saflex and Technical Specialties segments report improved Adjusted EBITDA margins
- The Company's cash generation in the quarter allowed for debt reduction of $50 million
- Diluted loss per share from continuing operations of $.04; Adjusted loss per share of $.05
- Maintaining Adjusted EBITDA guidance for the year of $325 million - $350 million
- Increasing 2009 target for cash from continuing operations less capital spending to $50 million - $100 million
New Term Loan
On May 5, 2009, a Solutia wholly owned German subsidiary entered into a $74 million, two-year senior unsecured term loan facility. The proceeds were used to pay down amounts under Solutia's credit facility.
Note: See reconciliation tables below for adjustments made to GAAP and discussion of items affecting results.
Consolidated Results from Continuing Operations
Solutia Inc. (NYSE: SOA) today reported a consolidated loss from continuing operations of $4 million for the first quarter of 2009, compared to income of $1,234 million for the same period in 2008. These results were impacted by certain events affecting comparability (detailed below) totaling a net gain of $1 million in 2009 and a net gain of $1,210 million in 2008. After adjusting for these items in both periods, co
'/>"/>
SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Related biology technology :1.
Solutia to Present at Deutsche Bank Small and Mid Cap Conference2.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound3.
QMed, Inc. Reports July Medicare SNP Enrollments4.
Phlo Affiliate Reports Expanded Coverage to Oregon Border5.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results6.
Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 20077.
Carrington Reports Second Quarter 2007 Results8.
Avitar Reports Third Quarter Financial Results for Fiscal 20079.
Response Genetics Reports Second Quarter 2007 Financial Results10.
Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results11.
Transgenomic, Inc. Reports Second Quarter 2007 Results